BioDelivery Sciences announces further insurance coverage for BELBUCA
BioDelivery Sciences International announced that several regional health care plans improved patient access to BELBUCA, CIII, during the second quarter of this year. Several prominent regional U.S. insurance plans representing an additional six million covered lives enhanced BELBUCA's coverage to preferred status or initiated coverage for BELBUCA. These six million covered lives brings the total number of commercial lives with access to BELBUCA to more than 165 million, representing more than 90% of the U.S. commercial insurance market. BELBUCA, CIII, is approved in the U.S. for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate. BELBUCA utilizes BDSI's patented BioErodible MucoAdhesive drug delivery technology to deliver buprenorphine, which is a Schedule III medicine. Schedule III drugs, substances, or chemicals are defined as drugs with a moderate to low potential for physical and psychological dependence. Schedule III drugs abuse potential is less than Schedule I and Schedule II drugs.